Neogen Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
NEOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neogen Chemicals reported its Q1 FY26 (quarter ended June 30, 2025) results: standalone revenue from operations rose about 4.7% YoY to Rs. 184.58 cr, with profit after tax of Rs. 14.23 cr versus Rs. 13.94 cr (restated). Consolidated revenue was Rs. 186.73 cr while PAT slipped to Rs. 10.26 cr from Rs. 11.47 cr, hit by higher finance costs and subsidiary losses. Prior-period numbers were restated to reflect the amalgamation of wholly owned subsidiary Buli Chemicals with effect from April 1, 2024. The auditor flagged an Emphasis of Matter on the March 2025 fire at the Dahej SEZ plant – the company has so far received Rs. 80 cr from the insurer with Rs. 254.06 cr still receivable against the Rs. 334.60 cr claim. Founder Chairman and MD Haridas Kanani will retire on September 30, 2025, and will be conferred the honorary title of Chairman Emeritus. The board also approved an additional Rs. 125 cr corporate guarantee for wholly owned subsidiary Neogen Ionics, raising contingent liabilities, and plans to raise up to Rs. 200 cr via NCDs on private placement.
Q1 numbers are largely flat to mildly positive on a standalone basis but weaker on a consolidated view, with a pending insurance recovery and rising finance costs likely to keep sentiment cautious. The founder's retirement marks a significant leadership transition, while the Rs. 125 cr guarantee to Neogen Ionics and the Rs. 200 cr NCD plan point to higher leverage and capital-raising activity that shareholders should monitor.